KNIGHT CAPITOL CONSULTANTS for GENZYME CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Budget and deficit reduction proposals that may affect the Medicare and Medicaid programs, including issues related to End Stage Renal Disease, and Sustainable Growth Rate and Average Sales Price calculations.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Pharmacy PHA
Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284).
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Taxation/Internal Revenue Code TAX
Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit and the Orphan Drug tax credit.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | previously listed |
Health Issues HCR
Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board. General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Prof Staff, House Appropriations Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.